articleTop 1% cited

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

The Lancet Oncology · 2009 · Vol. 11(1) · pp. 21–28

James A. Bonner✉(University of Alabama at Birmingham)Paul M. Harari(University of Wisconsin–Madison)J. Giralt(Vall d'Hebron Hospital Universitari)Roger B. Cohen(Fox Chase Cancer Center)Christopher U. JonesRanjan Sur(Hamilton Regional Laboratory Medicine Program)David Raben(University of Colorado Denver)José Baselga(Vall d'Hebron Hospital Universitari)Sharon A. Spencer(University of Alabama at Birmingham)Junming ZhuHagop YoussoufianEric K. RowinskyK. Kian Ang(The University of Texas MD Anderson Cancer Center)

View via DOI Publisher page

Head and Neck Cancer Studies Lung Cancer Treatments and Mutations Colorectal and Anal CarcinomasMedicineCetuximabHead and neck cancerClinical endpointRadiation therapyRashInternal medicineOncologyHead and neck squamous-cell carcinomaRandomized controlled trial

MeSH terms

CetuximabAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Squamous CellExanthemaFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm StagingSeverity of Illness Index

Citations

1,965

FWCI

103.94

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment